Tailoring the colorectal cancer disease assessment to the treatment strategy

摘要: The treatment options for metastatic colorectal cancer (CRC) continue to evolve with over 10 therapies now approved by the Food and Drug Administration for this indication. These include cytotoxic chemotherapeutics, biologics targeting vascular endothelial growth factor (VEGF) epidermal receptor, most recently approval of immunotherapeutic agents pembrolizumab nivolumab mismatch repair-deficient cancers. Additional BRAF mutant subtype CRC are likely be in near future. This growing number patients increases demand accurate disease assessments allow further setting benefit, also discontinuation or change strategy resistance. The Response Evaluation Criteria Solid Tumors (RECIST v1.1)1 is standard response criteria used oncology clinical trials loosely followed practice. For CRC, commonly done oral intravenous contrast enhanced CT imaging. use changes cross-sectional diameter quantify whether cancers …